Several studies have described a role for type I interferons (IFNab) in the initiation and/or prolongation of autoimmune diseases. Most pronounced has been the association of disease activity with what is now known as 'the interferon signature' of gene expression in peripheral blood mononuclear cells from lupus patients. In correlation, studies have shown that inhibition of IFNab signaling abrogates disease in various mouse models of lupus. New Zealand black (NZB) and B6.Nba2 congenic mice spontaneously develop elevated levels of serum anti-nuclear autoantibodies (ANAs). Nevertheless, neither of these strains develop fatal renal disease. The female F1 offspring of NZB or B6.Nba2 crossed with New Zealand white (NZW) mice do, however, develop kidney disease. We have previously shown that increases in endogenous IFNab levels in (B6.Nba2 Â NZW)F1 mice leads to accelerated development of renal disease in an IFNab-dependent manner. We now show that B6.Nba2 and (B6.Nba2 Â NZW)F1 mice deficient for the IFNab-receptor fail to develop ANA and renal disease, although the mice have substantial immune complex deposition in the glomeruli. Thus, endogenous IFNab might influence disease by affecting B-cell activation and differentiation, as well as the kidneys' susceptibility to damage, the latter perhaps through induction of a local inflammatory milieu.
Introduction
Murine systemic lupus erythematosus (SLE) is an autoimmune disease characterized by high levels of circulating immunoglobulin G (IgG) anti-nuclear autoantibodies (ANAs), glomerulonephritis, B-cell hyperactivity and polyclonal T-cell expansions. 1 Recently, SLE has been tightly associated with increased type I interferon (IFNab) activity in humans and in mouse models of spontaneous lupus-like disease. [2] [3] [4] Most strikingly, gene expression profile analyses have shown that peripheral blood mononuclear cells from SLE patients harbor a signature resembling that of cells exposed to IFNab, and that this signature can distinguish SLE patients from patients with rheumatoid arthritis. 3, 5 New Zealand hybrid mice are a well-studied mouse model of lupus-like disease. In these animals, the female F1 offspring of New Zealand black (NZB) crossed with New Zealand white (NZW) mice develops high levels of circulating autoantibodies against nuclear antigens such as DNA and histones, immune complex (IC) formation and deposition in the kidneys, and ultimately kidney failure due to damaged glomeruli. 6 Pathologically, lupus renal disease is characterized by IC deposition especially within the mesangium and capillary loops, a thickening of the glomerular basement membrane and hyperproliferation of glomerular cells. 1, 7 B6.Nba2 congenic animals express, on the C57BL/6 (B6) background, a locus (New Zealand black Autoimmunity 2 (Nba2)) from the distal part of chromosome 1 derived from NZB mice. 8 This locus has been associated with increased autoantibody production, and B6.Nba2 mice resemble NZB mice in their development of elevated levels of ANA directed against ssDNA, double-stranded DNA (dsDNA), total histones and chromatin. [8] [9] [10] Neither NZB nor B6.Nba2 mice, however, develop fatal kidney disease. 9 NZW mice do not develop elevated levels of ANA, but have been found to show increased susceptibility to anti-glomerular autoantibodyinduced kidney disease. 11 In addition, the female F1 offspring of NZW crossed with B6.Nba2 (but not B6) develops severe proteinuria and dies from kidney failure within 1 year of age as do female (NZB Â NZW)F1 mice. [8] [9] [10] Thus, the combination of Nba2-dependent autoantibody production and NZW-derived kidney susceptibility may be important for full disease development in the (B6.Nba2 Â NZW)F1 model of lupus-like disease.
We have previously shown that an increase in endogenous levels of IFNab caused by injection of polyI:C accelerated lupus-like disease development in young preautoimmune (B6.Nba2 Â NZW)F1 mice, and that neither parental strain was susceptible to this treatment. 4 To dissect this phenomenon in more detail, we examined the consequences of deleting the receptor for IFNab on B6.Nba2 and (B6.Nba2 Â NZW)F1 animals. In the current study, we found that IFNab-receptor 1 (IFNAR) deficiency led to reduced ANA production in B6.Nba2 mice. Interestingly, the mice still showed significant IC deposition in the kidneys, although none of the mice developed overt kidney disease. Further analyses showed that IFNAR-deficient mice had normalsized spleens with approximately normal cellular content. To analyze the effect of IFNAR deficiency on kidney disease development, we analyzed the female F1 offspring of IFNAR-deficient B6.Nba2 and NZW mice. These mice developed no measurable serum ANA, but had levels of IC deposition in the kidney glomeruli comparable to IFNAR-sufficient littermates. However, none of the mice developed renal disease. These data suggest that during lupus-like disease development in B6.Nba2 mice, IFNab might exert its effects at the following two levels: (1) the specificity of B cells that undergo activation and differentiation into plasma cells, and (2) the inflammatory milieu within the kidneys, making them more susceptible to antibody-inflicted damage.
Results
IFNAR-deficient B6.Nba2 mice produce less ANAs than IFNAR-sufficient littermates B6.Nba2 mice develop hypergammaglobulinemia starting at 2 months of age, 12 and elevated levels of circulating ANA starting at around 5 months of age. 8, 10, 13 We analyzed the serum levels of total IgM and IgG in 3- (Figures 1a and b) .
As IFNab signaling might influence the ratio of IgG1 to IgG2b production, we measured total IgG1 and IgG2b levels in serum from 3-month-old
and IFNAR À/À B6.Nba2 mice. The ratio of IgG1:IgG2b was significantly higher in IFNAR-deficient animals (Figure 1c) , predominantly due to lower levels of serum IgG2b in these mice (data not shown). There were no statistical significant differences in the ratio of IgG1:IgG2b between IFNAR (Figure 2 , middle panel, and data not shown). In contrast to parental B6.Nba2 mice, 8 few of the experimental mice in the current study (regardless of IFNAR expression levels) produced anti-dsDNA autoantibodies at 8 months of age ( Figure 2 , bottom panel), suggesting that background genes from 129/Sv mice are present and suppressive in these mice. This was further emphasized by a longitudinal analysis of ANA levels in sera from mice that were bled monthly from 3 to 11 months of age (Table 1) . Overall, IFNAR À/À B6.Nba2 mice produced significantly less anti-chromatin (Po0.0001) and anti-histone (Po0.05) IgG autoanti- 
) produced any significant levels of antidsDNA autoantibodies over time. (Figure 3b ). We also analyzed mice for deposition of IgG2b and IgG2c, as these (in combination with IgG3) are believed to be the major pathogenic IgG isotypes. 14 We found no differences in the amount and pattern of either IgG2b or IgG2c staining between IFNAR þ / þ and IFNAR À/À B6.Nba2 mice (Figure 3a) . Complement fixation to the glomerular walls has been suggested to play a major role in the pathogenicity of mouse lupus-like disease. We stained kidney sections for the presence of complement factor 3 (C3) and found that it was located both within the kidney glomeruli, an indicator of active complement fixation, as well as along the tubules in both IFNAR þ / þ and IFNAR À/À B6.Nba2 mice (Figure 3a) . Thus, fixation of complement had occurred in the mice regardless of IFNAR expression.
IFNAR-deficient B6.Nba2 mice do not develop splenomegaly and contain fewer memory CD4
þ T cells at older age Splenomegaly is a well-known characteristic of mouse lupus-like disease development in B6.Nba2 mice.
8, 12 We 
, n ¼ 50) produced significantly higher levels of anti-histone autoantibodies than did IFNAR-deficient littermates (n ¼ 14, Po0.05). Serum antichromatin levels were not statistically different between IFNARsufficient and IFNAR-deficient B6.Nba2 mice (P ¼ 0.14), but significantly increased in both groups as compared with nonautoimmune B6 females (Po0.0001 and Po0.01, respectively). None of the mice tested produced any anti-dsDNA autoantibodies above background. For all antibody specificities, the average level detected in age-matched B6 mice is given by the lower boundary of the y-axis: 0.04 U ml À1 anti-chromatin IgG, 0.33 U ml À1 anti-histone IgG, 0.83 U ml À1 anti-dsDNA IgG. dsDNA, double-stranded DNA; IFNAR, IFNab-receptor 1; Ig, immunoglobulin; Nba2, New Zealand black autoimmunity 2. (Table 3 ). There was also no difference in the percentage of CD8 Abbreviations: IFNAR, IFNab-receptor 1; Nba2, New Zealand black autoimmunity 2; ND, not done. 4-to 5-month-and 11-month-old mice were sacrificed and single cell suspensions were prepared from spleens. Cells were stained and analyzed for the expression of cell surface markers as described in Materials and methods. 15 Not surprising, the mice with the highest ratio of memory:naïve CD4 þ T cells were also the mice with the highest levels of anti-chromatin autoantibodies (r 2 ¼ 0.45, Po0.05, data not shown).
Ifi202 expression is reduced in IFNAR-deficient B6.Nba2 mice We have previously identified the Ifi202 gene as a potential lupus-susceptibility gene. 8 Ifi202 is mainly induced by IFNab, but to a lesser extent than by IFNg or interleukin-6 (ref. Pramanik et al. 16 and TN Jorgensen, unpublished observation). We analyzed whole spleens from IFNAR þ / þ , IFNAR þ /À and IFNAR À/À B6.Nba2 mice for expression levels of Ifi202. IFNAR-deficient mice had approximately twofold lower levels of basal Ifi202 expression than IFNAR-expressing littermates (Figure 4) . This difference was not statistically significant, but suggests that endogenous production of IFNab could in fact be accountable for some of the increased Ifi202 levels observed in B6.Nba2 mice. In addition, we analyzed total (B6.Nba2 Â NZW)F1 mice with control (B6.Nba2 Â NZW)F1 and non-autoimmune B6 mice, we found that the IFNAR-deficient mice failed to produce any significant amounts of any ANA measured (Figure 5a ), although only the lack of anti-dsDNA levels reached significance (Po0.05). Thus, in the presence of NZW-derived susceptibility genes, IFNAR deficiency affects ANA production.
As morphological differences and IC deposition within the kidneys are consistent with the development of renal disease, we analyzed kidney glomeruli from 12-month- (Figure 5c , Po0.01). It should be noted that the incidence of disease at 11 months was significantly lower in this cohort of IFNAR-expressing (B6.Nba2 Â NZW)F1 mice (46%) than in parental (B6.Nba2 Â NZW)F1 mice (80%, stippled line, Po0.05). This difference is most likely due to the only three generations of backcrossing of IFNAR deficiency to the NZW strain, resulting in either lack of NZW-derived susceptibility genes or the presence of non-NZW-derived protective genes.
Discussion
Several studies have aimed at elucidating the role of IFNab in mouse models of lupus. 4, [17] [18] [19] In NZB mice, IFNAR deficiency led to a reduction in disease IFNab receptor deficient B6.Nba2 mice TN Jørgensen et al characteristics including those involving autoantibody production and IgG deposition, 17 whereas treatment with recombinant IFNa accelerated disease. 18 Likewise, elevated IFNab levels accelerated disease in (B6.Nba2 Â NZW)F1 mice, although this effect was not seen in parental B6.Nba2 mice. 4 On the other hand, in MRL-Fas lpr mice, IFNAR deficiency exacerbated disease, resulting in higher levels of autoantibodies and more severe glomerulonephritis. 19 In the current study we have investigated IFNARdeficient B6.Nba2 congenic mice and the consequences of IFNAR deficiency for spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 Â NZW)F1 mice. We found that IFNAR À/À mice, regardless of ) were analyzed for kidney morphology by hematoxylin/eosin (H/E) staining and for IgG deposition and C3 levels by immunofluorescent staining. No differences were observed between kidneys from the two groups. (c) Mice were followed for the development of renal disease by detection of urine protein levels on a monthly basis. Mice with a measure of severe proteinuria (42 þ ) were retested within a week to avoid false positive measurements. While approximately half of the IFNAR-sufficient mice developed renal disease within 1 year, IFNAR-deficient mice failed to do so (Po0.01). C3, complement factor 3; dsDNA, double-stranded DNA; IFNAR, IFNabreceptor 1; Ig, immunoglobulin; Nba2, New Zealand black autoimmunity 2; NZW, New Zealand white.
background, produced reduced levels of serum autoantibodies to chromatin, total histones and dsDNA as compared with IFNAR
animals. In contrast, the patterns of IgG deposition and complement factor C3 fixation in the kidneys were similar between IFNAR þ / þ and IFNAR À/À mice, again regardless of background. There was also no difference in the levels of IgG2b/2c deposition in the kidneys, even though we detected an increased ratio of serum IgG1 to serum IgG2 in IFNAR-deficient animals (ref. 4 and this study). Most interestingly, IFNARdeficient (B6.Nba2 Â NZW)F1 mice failed to develop any renal disease, demonstrating a disconnection between autoantibody production, IC deposition and the development of renal disease.
At least two, not mutually exclusive, hypotheses could explain why the IFNAR À/À (B6.Nba2 Â NZW)F1 mice get less kidney disease: (1) the antibodies deposited in the kidneys of the IFNAR À/À mice could be less pathogenic, that is, have different specificities or (2) the inflammatory milieu of the kidneys from IFNAR-expressing and IFNARdeficient mice might be different, leading to higher susceptibilities to damage in IFNAR-expressing mice.
In support of the first idea, autoantibodies have been eluted from kidneys of lupus-prone mice. [20] [21] [22] [23] [24] These antibodies were found to bind mainly nuclear antigens such as chromatin, histones and dsDNA, and/or components of the glomerular basement membrane. In particular, anti-dsDNA autoantibodies were found to be pathogenic and it has been shown that some anti-dsDNA autoantibodies can by themselves alter the gene expression profile of mesangial cell lines, turning on the expression of inflammatory molecules. 24 Further studies are needed to evaluate whether the absence of antidsDNA autoantibodies in serum from IFNAR À/À (B6.Nba2 Â NZW)F1 mice is accountable for the lack of renal disease development in this model.
Alternatively, it has been suggested that the inflammatory milieu of the kidney can be affected by IFNab. A study by Patole et al. 25 investigated the effect of polyI:C, an IFNab-inducing component resembling viral dsRNA, on kidney cells. They found that mesangial cells expressed the dsRNA receptor toll-like receptor-3 and responded specifically to polyI:C treatment by producing chemokines and cytokines. It is believed that IFNab-receptors are expressed ubiquitously on virtually all cell types as a way of ensuring an immediate response to viral infections. A functional response to IFNab by mesangial cells has to our knowledge not been reported, however, gene expression data suggest that the MES-13 mouse mesangial cell line expresses both IFNab-receptors (NCBI database: GEO data set GSE2557 and GSE2558). It is therefore possible that elevated IFNab signaling can alter the physiology of glomerular cells and induce the production of various proinflammatory molecules causing inflammation by mononuclear cells. In this regard, it has been shown that type I interferons (IFNa or IFNb) can induce upregulated gene expression levels of numerous chemokines/chemokine receptors and proinflammatory cytokines (tumor necrosis factor-a and interleukin-6 in particular) after short-term stimulation. 26 Interestingly, some of these chemokines/chemokine receptors are expressed in kidneys of lupus-prone mice before the detection of autoantibodies and renal disease, 27 and in the kidneys of SLE patients with tubulo-interstitial lesions. 28 Several B-cell subsets have been suggested to be pathogenic in mouse lupus-like disease. These include marginal zone and B1a B cells. The percentages of marginal zone and B1a B cells were similar in the spleens of 11-month-old IFNAR-sufficient and -deficient B6.Nba2 mice. In correlation, studies of NZB mice showed equal percentages of B1 B cells, regardless of IFNAR levels. 17 Also, many lupus-prone mice, including NZB, are known to spontaneously develop germinal center-like structures very early in life, 29 and thus germinal center B cells might also play an important role in the disease process. Whether B6.Nba2 mice develop such structures is currently unknown.
T cells have been suggested to have an important, and in some cases even crucial, role for lupus-like disease development in mouse models of SLE. [30] [31] [32] [33] Analyses of splenocytes from 4-to 5-month-and 11-month-old IFNAR þ / þ , IFNAR þ /À and IFNAR À/À mice showed less of a shift with age in the ratio of memory-to-naive CD4 þ T cells in IFNAR-deficient mice. We have previously shown that IFNab are important for the maintenance, but not the activation, of CD4 þ T cells. 15 It is therefore possible that the T cells are activated appropriately in IFNAR-deficient mice, but are less likely to survive as memory cells. If that is the case, this could significantly affect the pattern of disease development in terms of T-cell-dependent B-cell activation, differentiation and autoantibody production.
Finally, our previous studies identified the interferoninducible gene Ifi202 as a major lupus candidate gene located in the Nba2 region. 8 Expression of Ifi202, and its human homolog IFI16, is regulated by interferons, most dramatically IFNabs (ref. Wang et al. 34 and Trapani et al., 35 and our unpublished data), and the proinflammatory cytokine interleukin-6. 16 Analyses of basal Ifi202 levels in total splenocytes from IFNAR
and IFNAR À/À B6.Nba2 mice showed that levels were reduced in mice in which IFNab signaling was abolished. Also, as expected, Ifi202 failed to get upregulated in IFNAR-deficient splenocytes after exposure to IFNabs in vitro. As Ifi202 is known to bind cell apoptosis and cycle control proteins such as p53BP and retinoblastoma protein, [36] [37] [38] the reduced levels of Ifi202 in total splenocytes from IFNAR-deficient B6.Nba2 mice may be directly related to the lack of splenomegaly in these mice.
In conclusion, our data support an important role for IFNabs during spontaneous development of renal disease in (B6.Nba2 Â NZW)F1 lupus-prone mice. These mice still deposited large amounts of IgG IC in the kidney glomeruli, suggesting that disease-related B-cell activation and autoantibody production were still occurring in these mice. Thus, either IFNabs promote the development of pathogenic autoantibodies required for the development of renal disease in this model or IFNabs advance the release of inflammatory molecules within the kidney itself leading to increased susceptibility of the kidney to IC-mediated damage.
Materials and methods

Mice
The congenic B6.NZB-Nba2 (B6.Nba2) strain was generated in our laboratory. 8 NZW/LacJ and B6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). IFNAR-deficient mice 39 were provided by Dr Aguet, ISREC (Lausanne, Switzerland), and backcrossed to B6.Nba2 (6-9 generations) and NZW (three generations). All mice studied were females. The mice were kept at the University of Colorado Health Sciences Center Animal Facility following US animal welfare guidelines, and as approved by the Animal and Care Use Committee of the University of Colorado Health Sciences Center (Denver, CO, USA). Mice were monitored for the development of proteinuria by dipsticks (Chemstrip 2 GP; Roche Diagnostics, Basel, Switzerland). Mice with proteinuria readings of X2 þ (100 mg dl À1 ) on two consecutive readings (less than 2 weeks apart) were designated as positive for severe proteinuria and renal disease.
Enzyme-linked immunosorbant assay
Enzyme-linked immunosorbant assays were performed as previously described. 4, 9, 40 For detection of total IgM, IgG, IgG2b and IgG1 levels, sera were diluted 1:50 000 and 1:100 000 in assay buffer (5 mg ml À1 bovine gglobulin, 5% gelatin, 0.05% Tween-20 in phosphatebuffered saline), while detection of antigen-specific autoantibodies was performed on 300-fold diluted sera. Standard curves were generated using serial dilutions of biotinylated purified mouse IgG, IgG1 or IgM (Caltag Laboratories, now Invitrogen, Carlsbad, CA, USA) for total immunoglobulin measurements or monoclonal antibodies against DNA (1D12) or histone 2A (2B1) for detection of antigen-specific autoantibodies as previously described. 9, 40 IgG2b was measured as relative optical density values. Concentrations are expressed in mg ml À1 for total IgG and IgM levels, and in U ml À1 for antigen-specific autoantibodies.
Immunohistochemistry
Kidneys were obtained from 11-to 12-month-old
B6.Nba2, and IFNAR þ / þ or IFNAR À/À (B6.Nba2 Â NZW)F1 mice. Half a kidney was fixed in 10% formalin and embedded in paraffin for immunohistochemical analyses. Sections (3 mm) were prepared and stained with periodic acidSchiff (PAS; Sigma-Aldrich, St Louis, MO, USA). Three independent sections (45 mm apart) were stained per sample and evaluated in a blinded manner. Glomeruli from IFNAR þ / þ or IFNAR À/À B6.Nba2 or (B6.Nba2 Â NZW)F1 were scored in a blinded manner on a scale from 0 to 2, where 0 represents no glomerular involvement; 1, increased cellularity involving o50% of the glomerulus and 2, increased cellularity involving 450% of the glomerulus. The scores for each group of mice were averaged and compared.
Another half of the kidney was quick-frozen in TissueTek (OCT) for immunofluorescence staining. Sections (5 mm) were cut, blocked with rabbit non-immune serum and stained for the presence of mouse IgG, IgG2b, IgG2c or complement factor C3, using a fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG antibody, Cy2-conjugated anti-mouse IgG2b, Texas-Red (TxR)-conjugated anti-mouse IgG2c or a fluorescein isothiocyanate-conjugated goat anti-mouse C3 antibody (all from MP Biomedicals, Solon, OH, USA). We analyzed at least two independent kidneys per genotype and 2-3 independent sections (480 mm apart) per sample. Microscopy and morphometric analyses were performed blinded on an Olympus BX51 microscope attached to a Pixera CL600 color CCD camera. We used the ImagePro software v4.5 program (Media Cybernetics, Silver Spring, MD, USA) for digital analyses. All pictures were taken with a fixed exposure time and are directly comparable within each experiment.
Fluorescence-activated cell sorting Mouse total splenocytes from 4-to 5-month-and 11-month-old IFNAR þ / þ , IFNAR þ /À and IFNAR À/À B6.Nba2 mice were stained with monoclonal antibodies conjugated to fluorescein isothiocyanate, phycoerythrin (PE), CyCychrome, APC or Alexafluor 647, and specific to mouse CD3, CD4, CD8, CD11b, CD11c, CD21, CD23, CD44, CD45R (B220), CD62L, CD122, IgM or IgD, and analyzed by flow cytometry on either a FACS Calibur (BD Biosciences, Franklin Lakes, NJ, USA) or a CyAn (Dako Cytomation, Glostrup, Denmark).
Sample preparation and real-time RT-PCR Single cells were prepared from spleens from 11-monthold IFNAR þ / þ , IFNAR þ /À and IFNAR À/À B6.Nba2 mice after removal of a snip of total spleen. Total spleen samples were homogenized for detection of basal levels of Ifi202 RNA. Spleen single cells were frozen in 10% dimethylsulfoxide, 20% fetal bovine serum in RPMI 1640 (Gibco, now Invitrogen) until all samples were acquired. Cells were then thawed, washed and plated in 96-well plates in the presence or absence of 500 U of recombinant IFNa (BioSource International, Camarillo, CA, USA) for 3 h. Plates were centrifuged at 1200 r.p.m., supernatants removed and cells frozen for isolation of RNA. RNA was prepared using the Qiagen RNeasy kits and following the manufacturer's protocol (Qiagen, Valencia, CA, USA). RNA was eluted in a final volume of 50-200 ml. 
Statistics
The statistical significance between of phenotypic differences between IFNAR þ / þ , IFNAR þ /À and IFNAR À/À mice, at single time points, was determined using an unpaired Student's t-test. Differences in autoantibody production over time (3-11 months of age) were determined by two-way analysis of variance using an unweighted means analysis. Briefly, autoantibodies in the mice were measured every month from 3 to 11 months of age. For each group of mice, the average levels of autoantibody production at each time point were calculated and plotted as a curve of mean U ml À1 versus the age of the mice. For each curve we calculated the area under the curve as a way to present all the data in a simpler way. Statistically significant differences between survival curves (proteinuria) were established by curve comparison analyses.
